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Discovery of a Novel Activator of KCNQ1-KCNE1 K+
Channel Complexes
Karen Mruk, William R. Kobertz*
Department of Biochemistry and Molecular Pharmacology, Programs in Neuroscience and Chemical Biology, University of Massachusetts Medical School, Worcester,
Massachusetts, United States of America
Abstract
KCNQ1 voltage-gated K+ channels (Kv7.1) associate with the family of five KCNE peptides to form complexes with diverse
gating properties and pharmacological sensitivities. The varied gating properties of the different KCNQ1-KCNE complexes
enables the same K+ channel to function in both excitable and non excitable tissues. Small molecule activators would be
valuable tools for dissecting the gating mechanisms of KCNQ1-KCNE complexes; however, there are very few known
activators of KCNQ1 channels and most are ineffective on the physiologically relevant KCNQ1-KCNE complexes. Here we
show that a simple boronic acid, phenylboronic acid (PBA), activates KCNQ1/KCNE1 complexes co-expressed in Xenopus
oocytes at millimolar concentrations. PBA shifts the voltage sensitivity of KCNQ1 channel complexes to favor the open state
at negative potentials. Analysis of different-sized charge carriers revealed that PBA also targets the permeation pathway of
KCNQ1 channels. Activation by the boronic acid moiety has some specificity for the Kv7 family members (KCNQ1, KCNQ2/3,
and KCNQ4) since PBA does not activate Shaker or hERG channels. Furthermore, the commercial availability of numerous
PBA derivatives provides a large class of compounds to investigate the gating mechanisms of KCNQ1-KCNE complexes.
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Introduction
The five KCNQ voltage-gated K+ channels (Kv7) are
responsible for membrane excitability, cardiac rhythmicity, and
maintaining salt and water homeostasis [1]. The KCNQ family is
divided by their tissue expression: KCNQ1 (Q1)1 channels are
expressed throughout the body, but are noticeably absent from the
central nervous system where KCNQ2–5 channels are primarily
found [2]. KCNQ2–5 subunits form homo- and heterotetrameric
K+ channels. KCNQ2/3 (Q2/Q3) contribute to the M-current
and mutations in these channels cause benign familial neonatal
convulsions (BFNC) [3]. Homotetrameric KCNQ4 (Q4) channels
have also been implicated in disease. Mutations in Q4 cause an
autosomal dominant form of progressive hearing loss in humans
[4,5]. In contrast, Q1 channels only form homotetramers and
function in non-excitable as well as excitable tissues [6]. In order to
properly function in these diverse tissues, Q1 channels co-assemble
with KCNE peptides, affording complexes with different gating
properties and pharmacological sensitivities [7]. Although KCNE
peptides promiscuously assemble with many voltage-gated K+
channels in expression systems [7], the physiological relevance of
most of the Q1-KCNE (E1, E2, and E3) complexes are well-
established. Q1 subunits form a complex with KCNE1 (E1)
peptides in the heart and inner ear, generating the cardiac IKs
current and providing an avenue for K+ to enter the endolymph,
respectively [8–10]. Mutations in either Q1 or E1 that decrease
the conductance of the complex prolong the cardiac action
potential [11], leaving individuals with these mutant proteins
susceptible to long QT syndrome. In contrast to the slowly
activating and deactivating Q1/E1 complex, both Q1/E2 and
Q1/E3 complexes are constitutively conducting and contribute to
K+ recycling in epithelial cells of the gastrointestinal tract [12,13].
Although the different KCNE peptides have diametrically
opposite effects on Q1 channel function, the molecular mecha-
nisms involved in KCNE modulation of Q1 channel gating are just
starting to be revealed [14–16]. Simple, small molecules that
activate Q1-KCNE complexes would be valuable tools for
investigating KCNE modulation of Q1 channel gating. Indeed,
low-affinity blockers such as the quaternary ammoniums have
been instrumental in the biophysical characterization of the
permeation pathway of K+ channels [17–20]. However, small
molecule activators of voltage-gated K+ channels are very rare
[21] and often synthetically challenging to derivatize. Moreover,
KCNE peptides are known to affect the sensitivity of pharmaco-
logical agents that modulate Q1 function [22]. Inhibitors of Q1
function are typically more potent when the channels are co-
assembled with KCNE peptides [23–26]. Conversely, small
molecules that activate homomeric Q1 channels are often
ineffective on Q1/E1 complexes. Two known examples of this
phenomenon are the Q1-specific activator, R-L3, and the recently
discovered KCNQ activator, zinc pyrithione [21,27,28]. The non-
specific Cl2 channel blockers, mefanamic acid and DIDS, are the
exception to the rule as they cross-react with and activate Q1/E1
complexes [26,29]. Thus, there remains a dearth of small molecule
activators for the biophysical study of Q1-KCNE complexes.
During our initial efforts to chemically activate Q1 channels by
specifically modifying the arginines in the voltage sensor, we
serendipitously discovered that some boronates were modulators
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of Q1/E1 complexes. Examination of a small panel of boronic
acids revealed that the aromatic derivative, phenylboronic acid
(PBA), activates Q1/E1 complexes at millimolar concentrations.
Activation of Q1/E1 by PBA is due to a shift in the voltage sensitivity
of the complex and is specific for the boronic acid moiety. The
permeation pathway is also affected by PBA since the magnitude of
Q1 channel activation is dependent on the charge carrier. PBA
shows some selectivity as it activates other members of the KCNQ
family, but does not activate Shaker or hERG K+ channels. Since
derivatives of PBA are common building blocks for organic synthesis,
there currently exists a vast array of structurally diverse phenyl-
boronic acids with varied physiochemical properties. The accessi-
bility to thousands of PBA derivatives provides an opportunity to
systematically dissect the mechanisms of Q1-KCNE gating and may
lead to the discovery of a potent activator of Q1/E1 complexes for
the treatment of cardiac arrhythmias.
Materials and Methods
Molecular Biology
cDNA encoding human KCNQ1, E1, and E3 were individually
subcloned into the vector pSG01MX, which contains the 59 and
39UTRs from the Xenopus b-globin gene for increased protein
expression. Inactivation-removed Shaker (Shaker-IR) was in
pBluescriptII KS (+). h-KCNQ2, Q3, and Q4 were kindly
provided by G. Seebohm and hERG was kindly provided by M.
C. Sanguinetti. The constructs were linearized with the appropri-
ate restriction enzyme (New England Biolabs) and cRNA was
synthesized using in vitro run-off transcription with SP6 or T7
polymerase (Promega).
Electrophysiology
Oocytes were surgically removed from Xenopus laevis. The
extraction procedure and care of Xenopus laevis was approved by
the University of Massachusetts Institutional Animal Care and Use
Committee. Oocytes were defolliculated using 2 mg/mL collage-
nase (Worthington Biochemical Corp.) in OR2 solution containing
(in mM): 82.5 NaCl, 2.5 KCl, 1 MgCl2, 5 HEPES, pH 7.4 for 60–
80 minutes. Isolated oocytes were rinsed and stored in ND96
storage solution containing (in mM): 96 NaCl, 2 KCl, 1.8 CaCl2, 1
MgCl2, 5 HEPES, 50 mg/mL of both gentamicin and tetracycline
pH 7.4, at 18uC. Oocytes were microinjected 24 h after surgery
with Shaker, Q1, Q4, or hERG mRNA (15.2 ng). Additionally,
Q1 mRNA (7.6 ng) was co-injected with E1 or E3 mRNA
(3.8 ng). For Q2/Q3 heteromeric channels, an equal amount of
mRNA (7.6 ng) for each subunit was injected. After 2–4 days,
currents were recorded using Warner Instrument OC-725 two-
electrode voltage clamp (TEVC), and the data were acquired with
Digidata 1322A using pClamp 9 (Axon Instruments). Electrodes
were filled with: 3 M KCl, 5 mM EGTA, 10 mM HEPES,
pH 7.6. Currents were measured in ND96 recording buffer
containing (in mM): 96 NaCl, 2 KOH, 0.3 CaCl2, 1 MgCl2, 10
HEPES, pH 7.6. All chemical compounds were from Sigma
Aldrich and dissolved directly into ND96 recording buffer to a
final concentration of 10 mM unless otherwise noted. For the
initial Borax experiments, 10 mM sodium tetraborate was used as
a buffer instead of HEPES. The time courses of current changes
upon compound application and washout were generated by
repeatedly depolarizing and measuring the change in current at
the end of the pulse. Channels were held at280 mV and pulsed to
+40 mV (0 mV for hERG) for 2 s (100 ms for Shaker) every 30 s
to illicit current. For EC50 experiments, current changes were
measured for a range of PBA concentrations (1–10 mM). Current-
voltage relationships were measured in the presence or absence of
10 mM PBA by holding at280 mV and stepping to a series of test
potentials for 4 s in 10 mV increments, followed by a tail pulse at
230 mV. For Q1/E3 complexes, the current-voltage relationships
were measured in KD50 containing (in mM): 48 NaCl, 50 KOH,
0.3 CaCl2, 1 MgCl2, 10 HEPES, pH 7.6 by holding at 280 mV
and pulsing to a series of potentials for 2 s in 20 mV increments,
followed by a tail pulse to 280 mV. For charge carrier
experiments, currents were measured in modified KD50 contain-
ing either 50 mM KOH, RbCl, or CsCl.
Data Analysis
Analysis of data was performed with Clampfit 9 (Axon
Instruments) and Prism 5 software (Graphpad). The maximal
change in current upon PBA washout at 40 mV was calculated as
Dgmax. EC50 values were calculated by plotting the Dgmax values as
a function of PBA concentration and fitting the data to a
hyperbola. The amplitude of tail currents was measured 6 ms
(100 ms for Q1) after repolarization to 230 mV (280 mV for
Q1/E3 and 50 mM external charge carriers) and normalized such
that the maximal tail current in the absence of drug was equal to 1.
Normalized tail currents were plotted versus the test potential to
produce activation curves. Activation curves were fit to the
Boltzmann equation: Itail = A1+(A22A1) / (1+e((V2VK)*(2zF/RT))),
where VK is the voltage of half-maximal activation and z is the
slope factor. A Student’s paired t-test was performed to determine
whether PBA activation was significantly different than activation
by benzyl alcohol. Deactivation time constants for Q1 were
measured after a depolarizing pulse to 40 mV and fitting the tail
current at 280 mV to a single exponential. Time constants were
fit after recovery from inactivation. For the comparison of outward
and inward currents, the amplitude of the Q1 current was
measured 2 s after depolarization for outward, 100 ms after
repolarization for inward. The outward and inward currents were
normalized to 1 after the onset of PBA inhibition (defined as
time= 0). Subsequent values were plotted as percent increase as a
function of PBA exposure time.
Results
Borax is a commonly used buffer for protein modification
reactions that specifically neutralizes positively charged arginine
residues [30]; thus, we initially determined whether borate buffer
would have any effect on Q1/E1 complexes. Figure 1A shows
normalized Q1/E1 current elicited by 40 mV, 2-s depolarizations
in standard ND96 buffer. Switching the solution to a buffer that
contains 10 mM sodium tetraborate resulted in reversible
inhibition of the Q1/E1 complex. Intrigued by the inhibitory
effect of borate, we determined whether boronic acid derivatives
had a similar effect on Q1/E1 complexes. Methylboronic acid in
ND96 with HEPES as the buffer had little to no effect on Q1/E1
complex function; however, perfusion of 10 mM phenylboronic
acid (PBA) caused a rapid inhibition followed by a slower
activation, resulting in a net doubling of current (Figure 1A).
Upon washout of PBA, inhibition was quickly and completely
relieved, resulting in a dramatic rise in current amplitude.
Although PBA’s inhibitory effect was rapidly reversible, activation
of Q1/E1 complexes slowly diminished upon removal of PBA, but
never fully washed out. To determine whether activation was due
to a shift in the voltage sensitivity of Q1/E1 complexes, we
measured the effect of PBA at different voltages (Figure 1B). Tail
current analysis (Figure 1C) in the presence PBA resulted in a left-
shift of the midpoint of activation (V1/2) and a decrease in the
voltage-dependence (z) of Q1/E1 complexes (Table 1). Since PBA
both activates and inhibits Q1/E1 complexes, we utilized the
Activator of Q1/E1 Complexes
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kinetic difference in washout to measure the maximal activation of
Q1/E1 complexes by PBA. Upon washout of PBA, inhibition was
quickly relieved resulting in a rapid rise in current (Figure 1A) and
the maximum current was measured and defined as Dgmax
(Table 1). Making this measurement with different concentrations
of PBA afforded an EC50 of 1.6 mM for Q1/E1 complexes.
To examine the importance of the boronic acid moiety, we
tested the structurally similar compounds: benzoic acid and benzyl
alcohol. Perfusion of benzoic acid reversibly inhibited Q1/E1
whereas benzyl alcohol reversibly activated the complex, but to a
lesser extent than PBA (Figure 1). Benzyl alcohol also had a
significantly smaller effect on the V1/2 of the complex compared to
PBA (Figure 1C and Table 1). Therefore, we subsequently
compared PBA and benzyl alcohol to determine whether the
geminal diol of the boronic acid would activate other K+ channels
and Q1-KCNE complexes.
Q1 channels co-expressed with KCNE3 (E3) were also activated
by PBA (Figure 2A). In contrast to Q1/E1, Q1/E3 currents were
primarily activated by PBA though a small amount of recovery
from inhibition was observed as a rapid increase in current when
the reagent was washed out. Since Q1/E3 complexes are open at
negative potentials, we used a high external potassium solution
Figure 1. Modulation of Q1/E1 channels by boronates. (A) Time course of Q1/E1 current measured in ND96 at +40 mV at the end of a 2 s
pulse. The current was normalized before compound application. Borax reversibly inhibits while methylboronic acid has little to no effect on channel
current. Phenylboronic acid (PBA) initially inhibits current and then slowly potentiates. Benzoic acid reversibly reduces Q1/E1 channel current whereas
benzyl alcohol reversibly activates the channel complex. (B) Families of currents recorded before and during treatment with PBA or benzyl alcohol.
Currents were elicited by 4 s step test potentials from 280 to +60 mV in 10 mV increments from a holding potential of 280 mV followed by a tail
pulse to 230 mV. Dashed line indicates zero current. Scale bars represent 1 mA and 0.5 s. (C) Voltage-activation curves for Q1/E1 calculated from tail
current analysis. Solid curves represent Boltzmann fits to the data. Data are presented as the mean6SEM (n = 10).
doi:10.1371/journal.pone.0004236.g001
Table 1. Electrophysiological Properties of KCNQ Channels in the presence of PBA or Benzyl Alcohol.a
Control Phenylboronic Acid (PBA) Benzyl Alcohol
V1/2 (mV) z D V1/2 (mV) D z Dgmax EC50 (mM) D V1/2 (mV) D z
Q1 231.861.6 2.3960.06 213.861.6* 0.5160.11 1.560.1 0.1060.02 24.665.5 0.5160.18
Q1/E1 23.461.2 1.7060.04 212.662.7* 20.2360.07 3.060.1 1.660.5 24.462.4 20.2360.07
Q1/E3 26.663.0 0.4760.02 3.365.4* 0.3360.04 3.960.2 6.165.7 2.764.9 0.3560.06
Q2/Q3 244.661.4 3.0860.11 29.862.3* 20.3260.34 3.060.3 3.761.4 25.962.9 0.3160.17
Q4 215.661.1 2.4560.06 213.761.3* 20.4460.11 .10 .10 20.862.9 20.5360.08
aData from individual activation curves obtained from 4–10 oocytes. Activation curves were fit to a Boltzmann function. VK is the voltage of half-maximal activation and
z is the slope factor. DV1/2 and D z are the changes induced by addition of 10 mM compound. Dgmax values were determined during the washout of inhibition, as
described in the Materials and Methods. EC50 values were determined during the washout of inhibition for PBA concentrations ranging from 1–10 mM. All values are
mean6SEM except for EC50 values, which are reported as the error of the fit to a hyperbola.
*Indicates significant (Student t-test; p,0.05) when compared to benzyl alcohol.
doi:10.1371/journal.pone.0004236.t001
Activator of Q1/E1 Complexes
PLoS ONE | www.plosone.org 3 January 2009 | Volume 4 | Issue 1 | e4236
(50 mM) to visualize both the outward and inward currents
generated from a family of test potentials (Figure 2B). Although
these conditions enabled us to measure the inward currents, Q1/
E3-expressing oocytes became unstable during the long time
course needed to observe complete activation by PBA (1000 s).
Therefore, we measured the current-voltage relationships after
500 s of PBA application (dashed arrow in Figure 2A). Tail current
analysis revealed that PBA activation of Q1/E3 complexes
occurred only at potentials greater than 240 mV (Figure 2C).
Accordingly, PBA did not shift the V1/2 of the complex, but
apparently increased the voltage dependence of the Q1/E3
complex (Table 1). This effect was not specific for the boronic
acid moiety because benzyl alcohol activated Q1/E3 similarly.
Since Q1-KCNE complexes were activated by PBA, we next
asked whether activation was KCNE-specific by examining other
members of the KCNQ family. Specifically, we examined the
physiologically relevant heterotetrameric Q2/Q3 channels and
homotetrameric Q4 channels. For homomeric Q1 channels,
activation by PBA was offset by inhibition, resulting in a negligible
increase in current. However, PBA significantly left-shifted the V1/2
of the channel and this activation was observed during washout
(Figure 3, Q1 panel). The overall effect of PBA on Q2/Q3
heterotetrameric channels was activation (Figure 3, Q2/Q3 panel).
Benzyl alcohol also activated Q2/Q3 channels, however, to
significantly lesser extent (Table 1). Strikingly, Q4 channels were
only activated by PBA (Figure 3, Q4 panel). A ,10-fold increase in
current was observed at 40 mV and the V1/2 of the complex was
significantly left-shifted (Table 1). Moreover, activation is specific for
the boronic acid moiety since benzyl alcohol did not shift the V1/2
(Table 1). To determine whether PBA activation was specific for
KCNQ family members, we examined two different voltage-gated
K+ channels: Shaker and hERG. Both the inactivation removed
variant of Shaker (Shaker-IR) and hERG were only reversibly
inhibited by 10 mM PBA (Figure 4). Therefore, activation by PBA
appears to be somewhat specific for KCNQ1-KCNE channel
complexes and KCNQ channels.
Because Q1 channels rapidly flicker between open and closed,
single channel events cannot be directly observed; therefore, we
indirectly determined whether PBA alters the permeation pathway
of Q1 channels during the potentiation phase. We examined PBA
potentiation in the presence of external cations with diameters
larger than K+ since the Q1 channel pore readily conducts both
Rb+ and Cs+ [31,32]. Oocytes expressing Q1 channels were
initially bathed in 50 mM external K+, Rb+, or Cs+. PBA (10 mM)
was added and after the onset of inhibition, the cell was
depolarized to 40 mV and returned to 280 mV to elicit outward
and inward currents, respectively (Figure 5, black traces). The
outward and inward currents were normalized and defined the
current level at time= 0. During the potentiation phase, outward
and inward currents were measured every 30 s until equilibrium
was reached (Figure 5, right graphs); the final trace is shown in
gray in the left panel of Figure 5. For K+, PBA caused a greater
increase in outward than inward current (Figure 5A) while in Rb+,
both outward and inward current increased equally (Figure 5B). In
Figure 2. PBA activates Q1/E3 complexes. (A) Time course of Q1/E3 current measured in ND96 at +40 mV at the end of a 2 s pulse. The current
was normalized before PBA application. PBA initially inhibits then slowly potentiates channel current. (B) Families of currents recorded in high
external potassium (50 mM) before and during treatment with PBA. Currents were elicited by 2 s test potentials from 2100 to +60 mV in 20 mV
increments. The holding and tail potentials were 280 mV. Dashed line indicates zero current. Scale bars represent 1 mA and 0.5 s. (C) Voltage-
activation curves for Q1/E3 calculated from tail current analysis. Solid curves represent Boltzmann fits to the data. Data are presented as the
mean6SEM (n= 10).
doi:10.1371/journal.pone.0004236.g002
Activator of Q1/E1 Complexes
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contrast, PBA caused a greater increase in inward than outward
currents when measured in Cs+ (Figure 5C). The deactivation
kinetics during the potentiation phase (Figure 5, insets) with the
different charge carriers were also measured. PBA slows Q1
channel closing when the larger Rb+ or Cs+ ions are charge
carriers whereas PBA has no significant effect on closing kinetics
with external K+ (Table 2). Since permeation and voltage-
dependent gating are intrinsically coupled in Q1 channels [32],
we also measured the PBA-induced changes in voltage sensitivity
with the different charge carriers (Table 3). PBA caused a
214 mV shift in the V1/2 of Q1 channels in both ND96 (2 mM
K+ext) and 50 mMK
+
ext (Table 1 and 3). However, in the presence
of the larger Rb+ and Cs+ ions, PBA left-shifted the V1/2 an
additional 6 mV. In total, these results show that activation of Q1
by PBA is dependent on the external charge carrier.
Discussion
Motivated by the fortuitous discovery that Borax modulates
Q1/E1 complexes, we determined whether the boronic acid
moiety was uniquely responsible for modulation of KCNQ
channels and KCNQ1-KCNE complexes. By examining struc-
turally different boronic acids, we found that the aromatic
derivative, PBA, activates Q1/E1 complexes at millimolar
concentrations. PBA activation of Q1/E1 is specific for the
boronic acid functional group because other similar aromatic
derivatives (benzyl alcohol and benzoic acid) are significantly less
effective or inhibitory. In contrast, both PBA and benzyl alcohol
similarly activate the Q1/E3 complexes. Activation of the
constitutively conducting Q1/E3 complex by PBA is only
observed at voltages greater than 240 mV, which ostensibly
increases the voltage-dependence of the complex. Homomeric Q1
channels are also modulated by PBA. At positive potentials, PBA
inhibits and activates Q1 channels equally, resulting in no net
change in current magnitude. Although PBA does not significantly
increase the total current, the voltage sensitivity of Q1 channels is
shifted with PBA such that they are open at more negative
potentials. These results suggest that the presence of the KCNE
peptides is not required for PBA to modulate the ion conducting
subunit; however, an overall increase in current magnitude is only
observed when Q1 channels co-assemble with KCNE peptides.
Thus, PBA is a more effective activator of Q1-KCNE complexes.
In addition to Q1 channels, PBA activates the other members of
the KCNQ family. Activation appears to be somewhat specific for
Figure 3. PBA activates all tested members of the KCNQ family. Left panel: Time courses of current recorded in ND96 at +40 mV at the end of
a 2 s pulse. The current was normalized before PBA application. PBA initially inhibits and then slowly potentiates Q1 and Q2/Q3 current. PBA only
activates Q4 channels. Middle panel: Families of currents recorded before and during treatment with PBA. Currents were elicited by 4 s test potentials
from 2100 to +60 mV in 10 mV increments from a holding potential of 280 mV followed by a tail pulse to 230 mV. Dashed line indicates zero
current. Scale bars represent 1 mA and 0.5 s. Right panel: Voltage-activation curves calculated from tail current analysis. Solid curves represent
Boltzmann fits to the data. Data are presented as the mean6SEM (n = 4–6).
doi:10.1371/journal.pone.0004236.g003
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KCNQ channels, as Shaker and hERG are not activated by PBA.
Comparing activation curve data for the KCNQ family indicated
that PBA activates these channels by shifting the midpoint of
activation (V1/2). The maximal increase of current (Dgmax) for
KCNQ channels at 40 mV is: Q4&Q1/E1<Q2/Q3.Q1. This
activation trend inversely correlates with the reported open
probabilities for KCNQ channels [33–36], suggesting a rationale
for the varied effectiveness of PBA. Testing this hypothesis,
however, is hampered by the flickery nature of Q1/E1 complexes,
which precludes the accurate measurement of the open probability
of these complexes by either single channel recordings or noise
analysis [37,38].
Without the ability to perform traditional single channel
analysis, we turned to Rb+ and Cs+ as charge carriers to indirectly
examine the effect of PBA on the Q1 permeation pathway. We
found that the inward and outward Q1 currents were differentially
potentiated by PBA. PBA increased Q1 outward currents
(compared to inward) when K+ was in the external bath and
inward currents when Cs+ was present. The asymmetry of PBA
activation of Q1 currents cannot be explained by increasing the
number of channels and thus points to modulation of the ion
conducting subunits. Consistent with this premise was the charge
carrier dependence of PBA potentiation: the larger the diameter of
the permeant ion, the more PBA increased the inward current
(Figure 5). This result suggests that PBA alters the Q1 selectivity
filter such that larger ions are more permeant. The larger Rb+ and
Cs+ ions also enhanced PBA’s effect on the V1/2 and deactivation
kinetics of Q1 channels compared to K+. Although the sum of
these results do not conclusively rule out an indirect modulatory
mechanism, the data in total strongly favor PBA directly
interacting with the KCNQ pore forming subunit.
One commonality of PBA modulation of KCNQ channels is the
slow onset of potentiation (minutes). If PBA is directly binding to
the channel, the slowed kinetics could be explained by a
cytoplasmic or buried binding site. PBA binding may in fact be
covalent, because boronic acids are known to form covalent, yet
reversible bonds with diols [39,40]. A covalent interaction is
consistent with the previous observations that chemical modifica-
tions activate KCNQ channels [14,15,35,41]. In addition, a slowly
reversible covalent interaction may also explain the lack of
Figure 4. PBA inhibits other Kv channels. (A) Time course of Shaker (inactivation removed) current measured in ND96 at +40 mV, 100 ms pulse
when 10 mM PBA was applied through the bath solution. (B) Families of Shaker currents recorded before and during treatment with PBA. Currents
were elicited by 100 ms step test potentials from 2100 to +60 mV in 10 mV increments from a holding potential of 280 mV. Dashed line indicates
zero current. Scale bars represent 1 mA and 0.1 s. (C) Time course of hERG current measured in ND96 at 0 mV, 2 s pulse when 10 mM PBA was
applied through the bath solution. (D) Families of hERG currents recorded before and during treatment with PBA. Currents were elicited by 2 s step
test potentials from 2100 to +60 mV in 10 mV increments from a holding potential of 280 mV. Dashed line indicates zero current. Scale bars
represent 1 mA and 0.5 s.
doi:10.1371/journal.pone.0004236.g004
Activator of Q1/E1 Complexes
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complete washout with some KCNQ channels (Figures 1A, 2A
and 3). Nonetheless, PBA may still be acting indirectly, activating
signaling pathways in the cell. However, these indirect pathways
must be specific for KCNQ channels since PBA activation was not
observed for Shaker and hERG channels.
While PBA activates KCNQ channels, it does inhibit Kv
channels weakly at 10 mM. Rapid inhibition was initially observed
for all Kv channels, except Q4. The trend for inhibition is:
Shaker.Q1<hERG<Q1/E1.Q2/Q3<Q1/E3. hERG inhibi-
tion is a concern for small molecule drug design; however, PBA
inhibition of hERG does not appear to occur by classic inner
vestibule block [42]. First, PBA is not a positively charged
molecule, which is typical for hERG blockers that bind to the
hydrophobic residues in the S6 helix [43]. Second, inhibition is not
specific for hERG, as the other Kv channels are similarly inhibited
at this high concentration of PBA. Given that PBA inhibition is
already weaker than activation for KCNQ channels, it should be
possible to design second generation boronic acid activators that
do not inhibit hERG and other Kv channels.
Unlike recently described activators of KCNQ channels, which
are rendered less effective when co-assembled with KCNE
peptides [27,28], PBA activates Q1-KCNE complexes more
Figure 5. Activation of Q1 by PBA is dependent on the external charge carrier ion. Current traces were recorded in (A) 50 mM K+, (B) Rb+,
or (C) Cs+. Left panel: Representative overlaid traces elicited by a +40 mV test and 280 mV tail pulse before and after the onset of PBA potentiation.
Inset: Normalized tail currents comparing the deactivation kinetics before and after the onset of PBA potentiation. Tick marks represent 200 ms. Right
panel: Time course of current recorded during the PBA potentiation phase. Outward current measured at the end of a 2 s pulse to +40 mV; maximal
inward current measured during the 280 mV tail pulse. Time zero is the amount of current after initial inhibition but before potentiation by PBA.
Data are represented as the mean6SEM (n= 5–10).
doi:10.1371/journal.pone.0004236.g005
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effectively than homotetrameric Q1 channels. Both of these
previous studies suggest that co-assembly with KCNE peptides
prevents R-L3 and zinc pyrithione from binding to the Q1
channel subunit [21,27,28]. Since PBA activates Q1-KCNE
complexes, future structure-function studies with PBA and other
boronic acids should provide insight into its binding site and yield
new tools to investigate the molecular mechanisms of Q1-KCNE
gating. Although the potency of this unoptimized, simple molecule
is modest, the non-toxicity of boronic acids (Borax), the catalogues
full of boronic acids derivatives, and their synthetic utility makes
PBA a potential pharmacophore for building potent activators of
Q1/E1 complexes. Moreover, since boronic acid-bearing com-
pounds are used clinically [44], their inclusion into small molecule
libraries would generate an array of potential KCNQ activators.
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